Joe Peppard and Colin Waugh join the board of directors. CEO and Chairman David Nash said, “We are delighted to welcome Joe Peppard and Colin Waugh to the board, they are highly accomplished experts who will bring a wealth of experience and insight to the company. They are excited by our vision and drive to use digital transformation to benefit healthcare systems globally. They come at an important juncture as the company looks to grow key areas of the business, including its prebuilt offering Vitro Elements and its cancer screening solution.”
Joe Peppard BBS MSc PhD FICS, is Principal Research Scientist at MIT’s Center for Information Systems Research (CISR), Sloan School of Management. He is also an Adjunct Professor at the University of South Australia, the University of Southern Queensland and Visiting Fellow at Durham University (UK). His most recent book is The Strategic Management of Information Systems: Building a Digital Strategy (Wiley, 2016) while his next book Taking the Reins as CIO: A Blueprint for Leadership Success (Palgrave Macmillan) will be published next year.
In his consulting, Joe advises large complex organisations on IT and strategy related matters, leveraging information and on how to unlock business value from their IT investments. He also works with several technology companies helping with their strategy, market positioning and growth. A former Irish international athlete, he is a Non-Executive Director of IT Alliance Group, an outsourcing and managed service provider, sits on the Irish Government’s eHealth Committee, and previously served as Chairman of the Board of Fineos Corporation (ASX:FCL), a global provider of innovative software solutions for insurance, bank assurance, and social insurance.
Colin Waugh spent much of his career in investment management, research and trading. He was a Partner, Portfolio Manager and Head of Research in the New York firm of Galtere Ltd, a $2.5bn global macro fund, until 2008 when he joined Lombard Street Research as an Associate Director for Commodities Research. He also worked in the commodities division of Merrill Lynch and was Vice president, Commodities at Shearson Lehman Brothers. He is currently on the Editorial Board of GCARD, the Global Commodity Applied Research Digest, at the J.P. Morgan Center for Commodities, University of Colorado Business School.
Colin has also been an early investor for over a decade in technology and health sector start-ups including Sense Networks (acquired by AT&T/Cerberus Capital) in the US and Point-2-Point Genomics in Europe. His investment involvement with Vitro Software began in 2011. He also holds a Certificate in Future Commerce from the Massachusetts Institute of Technology.
Colin has also worked extensively in Africa on development and migrant-related humanitarian projects and has published two non-fiction books about African political leaders: Paul Kagame and Rwanda (2004) and Charles Taylor and Liberia (2011). A recent member of the Advisory Board of Columbia University’s Institute of African Studies in New York and Associate fellow of Chatham House in London, Colin holds an MSc (Econ) degree from the London School of Economics and speaks French and Portuguese.